Effect of some peptides on dopaminergic function in man

Lal, Samarthji; Nair, N.P.V.; Isaac, Iona; Thavundayil, Joseph; Guyda, H.

doi:10.1007/978-3-7091-9050-0_17

Cited by 2 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There may be other routes by which desmopressin could exert CNS effects, for example by acting from the periphery to alter gene expression in the brain ( 95 ), binding to receptors in the periphery that feed back to the CNS, altering permeability of the blood-brain barrier to other substances ( 96 , 97 ), or by the formation of active fragments that can cross the blood-brain barrier following peripheral administration ( 98-101 ). In support of the ability of desmopressin to affect brain function, an inhibitory effect of intravenous desmopressin on hypothalamic dopamine function in humans has been reported ( 102 )-it was unclear whether this was a direct or indirect effect.…”

Section: Results Of Literature Review and Discussion Of Findingsmentioning

confidence: 99%

Potential clinical applications of current and future oral forms of desmopressin (Review)

Everaert,

Holm‑larsen,

Bou Kheir

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Desmopressin is a synthetic analogue of vasopressin and a selective vasopressin receptor 2 agonist. It was first synthesised in 1967 and utilised for its antidiuretic properties. It is also used in bleeding disorders to enhance clotting. Other potential uses of the drug have been reported. The present review aims to provide a broad overview of the literature on potential further uses of oral forms of desmopressin. Key therapeutic areas of interest were identified based on known physiological activities/targets of desmopressin or reports of an effect of desmopressin in the literature. The feasibility of adequate dosing with oral forms of the drug was also considered. Systematic literature searches were carried out using the silvi.ai software for the identified areas, and summaries of available papers were included in tables and discussed. The results of the searches showed that desmopressin has been investigated for its efficacy in a number of areas, including bleeding control, renal colic, the central nervous system and oncology. Evidence suggests that oral desmopressin may have the potential to be of clinical benefit for renal colic and bleeding control in particular. However, further research is needed to clarify its effect in these areas, including randomised controlled studies and studies specifically of oral formulations (and doses). Further research may also yield findings for cancer, cognition and overactive bladder. Contents 1. Introduction 2. Methods 3. Results of literature review and discussion of findings 4. Conclusion

show abstract

Section: Results Of Literature Review and Discussion Of Findingsmentioning

confidence: 99%

Potential clinical applications of current and future oral forms of desmopressin (Review)

Everaert,

Holm‑larsen,

Bou Kheir

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Typical (Lal et al, 1973(Lal et al, , 1977Rotrosen et al, 1979) and atypical neuroleptics, including clozapine (Nair et al, 1979) and the D-2 receptor antagonist, sulpiride , antagonize the GH response to Apo, and, neuroleptics (except clozapine) increase basal PRL secretion (Nair et al, 1979;Langer et al, 1977;Gruen et al, 1978). The GH response to Apo has been used to assess DA function in schizophrenia (Lal, 1987) and other disorders (Lal, 1988) and to investigate the effect of steroids (Ettigi et al, 1975;Lal et al, , 1988, peptides (Lal et al, 1983(Lal et al, , 1990) and other psychopharmacological agents (Lal et al, 1978;Ettigi et al, 1976) as well as various treatment modalities in psychiatry (sleep deprivation, electroconvulsive therapy) (Lal et al, 1981;Costain et al, 1982) on DA function in man. Elevation of serum PRL levels in response to pharmacological agents has been proposed as a screening method for detecting antischizophrenic agents (Gruen et al, 1978).…”

Section: Introductionmentioning

confidence: 99%

Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man

et al. 1991

J. Neural Transmission

Self Cite

View full text Add to dashboard Cite

The stereospecificity of the D-2 receptor mediating the growth hormone (GH) response to apomorphine (Apo) and the D-2 receptor regulating prolactin (PRL) secretion were investigated in 10 normal men by examining the effects of cis-flupenthixol (cis-Fx) and trans-flupenthixol (trans-Fx). cis-Fx (1 mg six hourly times four doses) antagonized the GH response to Apo HCl (0.5 mg sc) and increased basal serum PRL concentrations whereas the trans-isomer showed no effect. These findings (a) provide further evidence that the GH response to Apo is mediated by stimulating dopamine (DA) receptors, and, (b) demonstrate stereospecificity of the DA receptor mediating the GH response to Apo and the DA receptor regulating PRL secretion.

show abstract

Effect of some peptides on dopaminergic function in man

Cited by 2 publications

References 48 publications

Potential clinical applications of current and future oral forms of desmopressin (Review)

Potential clinical applications of current and future oral forms of desmopressin (Review)

Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man

Contact Info

Product

Resources

About